Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
| Autor: | Claire Feeney, Gil Yosipovitch, Daniela E. Myers, Chia-Yu Chu, Fan Zhang, Jacob P. Thyssen, Shawn G. Kwatra, Ricardo Rojo, Carle Paul, Hernan Valdez, Marco DiBonaventura |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Moderate to severe medicine.medical_specialty Eczema Phases of clinical research Dermatology Placebo Hospital Anxiety and Depression Scale Severity of Illness Index Dermatitis Atopic Subcutaneous injection Double-Blind Method Internal medicine medicine Humans Patient Reported Outcome Measures Sulfonamides business.industry Atopic dermatitis Dermatology Life Quality Index medicine.disease Dupilumab Pyrimidines Treatment Outcome Infectious Diseases business |
| Zdroj: | Thyssen, J P, Yosipovitch, G, Paul, C, Kwatra, S G, Chu, C Y, DiBonaventura, M, Feeney, C, Zhang, F, Myers, D, Rojo, R & Valdez, H 2022, ' Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 3, pp. 434-443 . https://doi.org/10.1111/jdv.17813 |
| ISSN: | 1468-3083 0926-9959 |
| Popis: | Background: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. Objectives: We examined clinically meaningful improvements in selected patient-reported outcomes (PROs). Methods: JADE COMPARE was a multicentre, phase 3 randomized, double-blind, placebo-controlled trial. Adults with moderate-to-severe AD were randomized 2:2:2:1 to receive 16 weeks of oral abrocitinib 200 or 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo, with background topical therapy. PROs included Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Night Time Itch Scale (NTIS), Pruritus and Symptoms Assessment for Atopic Dermatitis, Patient Global Assessment, SCORing Atopic Dermatitis, and Hospital Anxiety and Depression Scale. Results: At week 16, the proportion of patients achieving POEM scores |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text